Lower urinary tract symptoms (LUTS), overactive bladder syndrome (OAB) and detrusor overactivity (DO) are all conditions that can have major effects on quality of life and social functioning. Antimuscarinic drugs are first-line treatment-they often have good initial response rates, but adverse effects and decreasing efficacy cause long-term compliance problems, and alternatives are needed. The recognition of the functional contribution of the urothelium, the spontaneous myocyte activity during bladder filling, and the diversity of nerve transmitters has sparked interest in both peripheral and central modulation of LUTS/OAB/DO pathophysiology. There may be several new possibilities to treat LUTS/OAB/DO. β3-AR agonists (YM178), PDE 5 inhibitors (sildenafil, tadalafil, vardenafil), vitamin D analogs (elocalcitol), combinations (α1-AR antagonist + antimuscarinic), and drugs with a central mode of action (tramadol, aprepitant) all have Randomized controlled trial (RCT) documented efficacy. Which of these therapeutic principles will be developed to clinically useful treatments remains to be established.
Andersson, K.E. (1993) Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev45: 253-308.
2.
Andersson, K.E. (1999) Pathways for Relaxation of detrusor smooth muscle , in Baskin, L.S. and Hayward, S.W. (eds) Advances in Bladder Research . Kluwer Academic/Plenum Publishers: New York, 241-252.
Andersson, K.E. (2008) How many drugs for LUTS due to BPH are too many ? J Urol180: 811-2.
7.
Andersson, K.E. and Arner, A. (2004) Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev84: 935-86.
8.
Andersson, K.E., Chapple, C.R., Cardozo, L., Cruz, F., Hashim, H., Michel, M.C. et al. (in press) Pharmacological treatment of urinary incontinence , P. Abrams, L. Cardozo, S. Khoury, & A. Wein (eds) Incontinence, 4nd International Consultation on Incontinence. Plymbridge Distributors Ltd: Plymouth, UK.
9.
Andersson, K.E. and Pehrson, R. (2003) CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs63: 2595-611.
10.
Aschkenazi, S., Botros, S., Miller, J., Gamble, T., Sand, P. and Goldberg, R. (2007) Overactive bladder symptoms are not related to detrusor overactivity. Neurourol Urodyn26: 35.
11.
Athanasopoulos, A., Gyftopoulos, K., Giannitsas, K., Fisfis, J., Perimenis, P. and Barbalias, G. (2003)
12.
Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol169: 2253-6.
13.
Badawi, J.K., Seja, T., Uecelehan, H., Honeck, P., Kwon, S.T., Bross, S. et al. (2007) Relaxation of human detrusor muscle by selective beta-2 and beta-3 agonists and endogenous catecholamines. Urology69: 785-90.
14.
Biers, S.M., Reynard, J.M. and Brading, A.F. (2006) The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int98: 1310-14.
15.
Birder, L.A. and de Groat, W.C. (2007) Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol4: 46-54.
16.
Birder, L., Kullmann, F.A., Lee, H., Barrick, S., de Groat, W., Kanai, A. et al. (2007) Activation of urothelial transient receptor potential vanilloid 4 by 4alpha-phorbol 12,13-didecanoate contributes to altered bladder reflexes in the rat. J Pharmacol Exp Ther323: 227-35.
17.
Carbone, A., Palleschi, G., Conte, A., Bova, G., Iacovelli, E., Bettolo, R.M. et al. (2006) Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol29: 206-14.
18.
Chapple, C.R., Yamaguchi, O., Ridder, A., Liehne, J., Carl, S., Mattiassin, A. et al. (2008) Clinical proof of concept study (Blossom) shows novel B3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl7: 239.
19.
Christ, G.J. and Andersson, K.E. (2007) Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn26: 948-54.
20.
Colli, E., Digesu, G.A. and Olivieri, L. (2007) Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs16: 999-1007.
21.
Combrisson, H., Allix, S. and Robain, G. (2007) Influence of temperature on urethra to bladder micturition reflex in the awake ewe. Neurourol Urodyn26: 290-5.
22.
Covenas, R., Martin, F., Belda, M., Smith, V., Salinas, P., Rivada, E. et al. (2003) Mapping of neurokinin-like immunoreactivity in the human brainstem. BMC Neurosci4: 3.
23.
Crescioli, C., Ferruzzi, P., Caporali, A., Scaltriti, M., Bettuzzi, S., Mancina, R. et al. (2002) Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Mol Cell Endocrinol198: 69-75.
24.
Crescioli, C., Ferruzzi, P., Caporali, A., Mancina, R., Comerci, A., Muratori, M. et al. (2003) Inhibition of spontaneous and androgen-induced prostate growth by a nonhypercalcemic calcitriol analog. Endocrinology144: 3046-57.
25.
Crescioli, C., Ferruzzi, P., Caporali, A., Scaltriti, M., Bettuzzi, S., Mancina, R. et al. (2004) Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia. Eur J Endocrinol150: 591-603.
26.
Crescioli, C., Morelli, A., Adorini, L., Ferruzzi, P., Luconi, M., Vannelli, G.B. et al. (2005) Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab90: 962-72.
27.
Cruz, F., Charrua, A., Cruz, C., Gharat, L., Gullapalli, S., Narayanan, S. et al. (2008) GRC 6211, a new oral TROV1 antagonist, decreases the frequency of bladder reflex contractions and noxious input in rats with acute or chronic cystitis. Eur Urol Suppl7: 181.
28.
Digesu, G.A., Khullar, V., Cardozo, L. and Salvatores, S. (2003) Overactive bladder symptoms: do we need urodynamics ? Neurourol Urodyn22: 105-8.
29.
Drake, M.J. (2008) Emerging drugs for treatment of overactive bladder and detrusor overactivity. Expert Opin Emerg Drugs13: 431-46.
30.
Du, S., Araki, I., Yoshiyama, M., Nomura, T. and Takeda, M. (2007) Transient receptor potential channel A1 involved in sensory transduction of rat urinary bladder through C-fiber pathway. Urology70: 826-31.
31.
Fowler, C.J., Griffiths, D. and de Groat, W.C. (2008) The neural control of micturition. Nat Rev Neurosci9: 453-66.
32.
Frazier, E.P., Mathy, M.J., Peters, S.L. and Michel, M.C. (2005) Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? J Pharmacol Exp Ther313: 260-7.
33.
Frazier, E.P., Peters, S.L., Braverman, A.S., Ruggieri Sr, M.R. and Michel, M.C. (2008) Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors . Naunyn Schmiedebergs Arch Pharmacol377: 449-62.
34.
Fujimura, T., Tamura, K., Tsutsumi, T., Yamamoto, T., Nakamura, K., Koibuchi, Y. et al. (1999) Expression and possible functional role of the beta3-adrenoceptor in human and rat detrusor muscle. J Urol161: 680-5.
35.
Gee, N.S., Brown, J.P., Dissanayake, V.U., Offord, J., Thurlow, R. and Woodruff, G.N. (1996) The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem271: 5768-76.
36.
Gevaert, T., Vriens, J., Segal, A., Everaerts, W., Roskams, T., Talavera, K. et al. (2007) Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest117: 3453-62.
37.
Giembycz, M.A. (2005) Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol5: 238-44.
38.
Gillespie, J.L. (2004) Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder. BJU Int93: 1325-32.
39.
Gratzke, C., Streng, T., Waldkirch, E., Sigl, K., Stief, C., Andersson, K.E. et al. (2009) Transient Receptor Potential A1 (TRPA1) Activity in the Human Urethra-Evidence for a Functional Role for TRPA1 in the Outflow Region . Eur Urol55: 696-704.
40.
Green, S.A., Alon, A., Ianus, J., McNaughton, K.S., Tozzi, C.A. and Reiss, T.F. (2006) Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence. J Urol176: 2535-40.
41.
Griffiths, D. (2007) Imaging bladder sensations. Neurourol Urodyn26: 899-903.
42.
Griffiths, D. and Tadic, S.D. (2008) Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. Neurourol Urodyn27: 466-74.
43.
Grond, S. and Sablotzki, A. (2004) Clinical pharmacology of tramadol. Clin Pharmacokinet43: 879-923.
44.
Gu, B.J., Ishizuka, O., Igawa, Y., Nishizawa, O. and Andersson, K.E. (2000) Role of supraspinal tachykinins for micturition in conscious rats with and without bladder outlet obstruction. Naunyn Schmiedebergs Arch Pharmacol361: 543-8.
45.
Hashim, H. and Abrams, P. (2004) Do symptoms of overactive bladder predict urodynamics detrusor overactivity? NeuroUrol Urodyn23: 484-486.
46.
Hicks, A., McCafferty, G.P., Riedel, E., Aiyar, N., Pullen, M., Evans, C. et al. (2007) GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther323: 202-9.
47.
Hiragata, S., Ogawa, T., Hayashi, Y., Tyagi, P., Seki, S., Nishizawa, O. et al. (2007) Effects of IP-751, ajulemic acid, on bladder overactivity induced by bladder irritation in rats. Urology70: 202-208.
48.
Holstege, G. (2005) Micturition and the soul. J Comp Neurol493: 15-20.
49.
Hudman, D., Elliott, R.A. and Norman, R.I. (2000) K(ATP) channels mediate the beta(2)-adrenoceptor agonist-induced relaxation of rat detrusor muscle. Eur J Pharmacol397: 169-76.
50.
Hyman, M.J., Groutz, A. and Blaivas, J.G. (2001) Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol166: 550-2.
51.
Igawa, Y., Yamazaki, Y., Takeda, H., Hayakawa, K., Akahane, M., Ajisawa, Y. et al. (1999) Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol126: 819-25.
52.
Igawa, Y., Yamazaki, Y., Takeda, H., Kaidoh, K., Akahane, M., Ajisawa, Y. et al. (2001) Relaxant effects of isoproterenol and selective beta3-adrenoceptor agonists on normal, low compliant and hyperreflexic human bladders. J Urol165: 240-4.
53.
Irwin, D.E., Milsom, I., Hunskaar, S., Reilly, K., Kopp, Z., Herschorn, S. et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol50: 1306-14.
54.
Ishizuka, O., Igawa, Y., Lecci, A., Maggi, C.A., Mattiasson, A. and Andersson, K.E. (1994) Role of intrathecal tachykinins for micturition in unanaesthetized rats with and without bladder outlet obstruction. Br J Pharmacol113: 111-6.
55.
Ishizuka, O., Igawa, Y., Nishizawa, O. and Andersson, K.E. (2000) Role of supraspinal tachykinins for volume- and L-dopa-induced bladder activity in normal conscious rats. Neurourol Urodyn19: 101-9.
56.
Ishizuka, O., Mattiasson, A. and Andersson, K.E. (1995) Effects of neurokinin receptor antagonists on L-dopa induced bladder hyperactivity in normal conscious rats. J Urol154: 1548-51.
57.
Kaidoh, K., Igawa, Y., Takeda, H., Yamazaki, Y., Akahane, S., Miyata, H. et al. (2002) Effects of selective beta2 and beta3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol168: 1247-52.
58.
Kaiho, Y., Nishiguchi, J., Kwon, D.D., Chancellor, M.B., Arai, Y., Snyder, P.B. et al. (2008) The effects of a type 4 phosphodiesterase inhibitor and the muscarinic cholinergic antagonist tolterodine tartrate on detrusor overactivity in female rats with bladder outlet obstruction. BJU Int101: 615-20.
59.
Kaplan, S.A., Roehrborn, C.G., Rovner, E.S., Carlsson, M., Bavendam, T. and Guan, Z. (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA296: 2319-28.
60.
Kim, Y.T., Kwon, D.D., Kim, J., Kim, D.K., Lee, J.Y. and Chancellor, M.B. (2004) Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int Braz J Urol30: 275-8.
61.
Lecci, A. and Maggi, C.A. (2001) Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system. Regul Pept101: 1-18.
62.
Lee, K.S., Choo, M.S., Kim, D.Y., Kim, J.C., Kim, H.J., Min, K.S. et al. (2005) Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol174: 1334-8.
63.
Lee, J.Y., Kim, H.W., Lee, S.J., Koh, J.S. and Suh, H.J. (2004) Chancellor MB.Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int94: 817-20.
64.
Leon, L.A., Hoffman, B.E., Gardner, S.D., Laping, N.J., Evans, C., Lashinger, E.S. et al. (2008) Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats . J Pharmacol Exp Ther326: 178-85.
65.
Longhurst, P.A., Briscoe, J.A., Rosenberg, D.J. and Leggett, R.E. (1997) The role of cyclic nucleotides in guinea-pig bladder contractility. Br J Pharmacol121: 1665-72.
66.
Maneuf, Y.P., Gonzalez, M.I., Sutton, K.S., Chung, F.Z., Pinnock, R.D. and Lee, K. (2003) Cellular and molecular action of the putative GABA-mimetic, gabapentin. Cell Mol Life Sci60: 742-50.
67.
Massaro, A.M. and Lenz, K.L. (2005) Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother39: 77-85.
68.
McConnell, J.D., Roehrborn, C.G., Bautista, O.M., Andriole Jr, G.L., Dixon, C.M., Kusek, J.W. et al. (2003) Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med349: 2387-98.
69.
McVary, K.T. (2007) A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther29: 387-98.
McVary, K.T., Monnig, W., Camps Jr, J.L., Young, J.M., Tseng, L.J. and van den Ende, G. (2007b) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol177: 1071-7.
72.
Michel, M.C. and Vrydag, W. (2006) Alpha1-, alpha2-and beta-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol147: S88-119.
73.
Mongin, G. (2007) Tramadol extended-release formulations in the management of pain due to osteoarthritis. Expert Rev Neurother7: 1775-84.
74.
Morelli, A., Vignozzi, L., Filippi, S., Vannelli, G.B., Ambrosini, S., Mancina, R. et al. (2007) BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate67: 234-47.
75.
Morita, T., Iizuka, H., Iwata, T. and Kondo, S. (2000) Function and distribution of beta3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphincter. J Smooth Muscle Res36: 21-32.
76.
Nishiguchi, J., Kwon, D.D., Kaiho, Y., Chancellor, M.B., Kumon, H., Snyder, P.B. et al. (2007) Suppression of detrusor overactivity in rats with bladder outlet obstruction by a type 4 phosphodiesterase inhibitor . BJU Int99: 680-6.
77.
Nomiya, M. and Yamaguchi, O. (2003) A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol170: 649-53.
78.
Novara, G., Galfano, A., Ficarra, V. and Artibani, W. (2006) Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review. Eur Urol50: 675-83.
79.
Otsuka, A., Shinbo, H., Matsumoto, R., Kurita, Y. and Ozono, S. (2008) Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol377: 473-81.
80.
Pehrson, R. and Andersson, K.E. (2003) Tramadol inhibits rat detrusor overactivity caused by dopamine receptor stimulation. J Urol170: 272-5.
81.
Pehrson, R., Stenman, E. and Andersson, K.E. (2003) Effects of tramadol on rat detrusor overactivity induced by experimental cerebral infarction. Eur Urol44: 495-9.
82.
Peters, S.L., Schmidt, M. and Michel, M.C. (2006) Rho kinase: a target for treating urinary bladder dysfunction? Trends Pharmacol Sci27: 492-7.
83.
Roehrborn, C.G., Siami, P., Barkin, J., Damião, R., Major-Walker, K., Morrill, B. et al. (2008) CombAT Study Group. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. Urol 2008179: 616-21.
84.
Rovner, E.S., Kreder, K., Sussman, D.O., Kaplan, S.A., Carlsson, M., Bavendam, T. and Guan, Z. (2008) Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol180: 1034-41.
85.
Ruggieri Sr, M.R., Braverman, A.S. and Pontari, M.A. (2005) Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol174: 1743-8.
86.
Sacco, E., Pinto, F. and Bassi, P. (2008) Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct19: 583-98.
87.
Safarinejad, M.R. and Hosseini, S.Y. (2006) Safety and efficacy of tramadol in the treatment of idiopathic detrusor overactivity: a double-blind, placebo-controlled, randomized study. Br J Clin Pharmacol61: 456-63.
88.
Saffroy, M., Torrens, Y., Glowinski, J. and Beaujouan, J.C. (2003) Autoradiographic distribution of tachykinin NK2 binding sites in the rat brain: comparison with NK1 and NK3 binding sites . Neuroscience116: 761-73.
89.
Sairam, K., Kulinskaya, E., McNicholas, T.A., Boustead, G.B. and Hanbury, D.C. (2002) Sildenafil influences lower urinary tract symptoms . BJU Int90: 836-9.
90.
Schröder, A., Colli, E., Maggi, M. and Andersson, K.E. (2006) Effects of a vitamin D3 analogue in a rat model of bladder outflow obstruction. BJU Int98: 637-42.
91.
Seki, S., Erickson, K.A., Seki, M., Nishizawa, O., Igawa, Y., Ogawa, T. et al. (2005) Elimination of rat spinal neurons expressing neurokinin 1 receptors reduces bladder overactivity and spinal c-fos expression induced by bladder irritation. Am J Physiol Renal Physiol288: F466-73.
92.
Singh, S.K., Agarwal, M.M., Batra, Y.K., Kishore, A.V. and Mandal, A.K. (2008) Effect of lumbar-epidural administration of tramadol on lower urinary tract function. Neurourol Urodyn27: 65-70.
93.
Steers, W.D., Herschorn, S., Kreder, K.J., Moore, K., Strohbehn, K., Yalcin, I. et al. (2007) Duloxetine OAB Study Group. Duloxetine compared with placebo for treating women with symptoms of overactive bladder. BJU Int100: 337-45.
94.
Stief, C.G., Porst, H., Neuser, D., Beneke, M. and Ulbrich, E. (2008) A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol53: 1236-44.
95.
Streng, T., Axelsson, H.E., Hedlund, P., Andersson, D.A., Jordt, S.E., Bevan, S. et al. (2008) Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol53: 391-9.
96.
Striano, P. and Striano, S. (2008) Gabapentin: a Ca2+ channel alpha 2-delta ligand far beyond epilepsy therapy. Drugs Today ( Barc) 44: 353-68.
97.
Takeda, M., Obara, K., Mizusawa, T., Tomita, Y., Arai, K., Tsutsui, T. et al. (1999) Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther288: 1367-73.
98.
Takasu, T., Ukai, M., Sato, S., Matsui, T., Nagase, I., Maruyama, T. et al. (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther321: 642-7.
99.
Takeda, H., Yamazaki, Y., Igawa, Y., Kaidoh, K., Akahane, S., Miyata, H. et al. (2002) Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats. Neurourol Urodyn21: 558-65.
100.
Truss, M.C., Stief, C.G., Uckert, S., Becker, A.J., Schultheiss, D., Machtens, S. et al. (2000) Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. World J Urol18: 439-443.
101.
Truss, M.C., Stief, C.G., Uckert, S., Becker, A.J., Wefer, J., Schultheiss, D. et al. (2001) Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol19: 344-350.
102.
Uchida, H., Shishido, K., Nomiya, M. and Yamaguchi, O. (2005) Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via beta-adrenoceptors . Eur J Pharmacol518: 195-202.
103.
Uckert, S., Kuthe, A., Jonas, U. and Stief, C.G. (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol166: 2484-90.
104.
Woods, M., Carson, N., Norton, N.W., Sheldon, J.H. and Argentieri, T.M. (2001) Efficacy of the beta3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol166: 1142-7.
105.
Yoshimura, N., Kaiho, Y., Miyazato, M., Yunoki, T., Tai, C., Chancellor, M.B. et al. (2008) Therapeutic receptor targets for lower urinary tract dysfunction. Naunyn Schmiedebergs Arch Pharmacol377: 437-48.
